EUROMEDICA  Hanover 3-4  Juni 2010	Advanced methods of diagnosis, treatment and prophylactics
	European Academy of Natural Sciences, Hanover European Scientific Society, Hanover Berliner Medizinischen Gesellschaft, Berlin

Home

Abstracts

Contact

Disclaimer

The clinical trial of patented medical technology “Semicarbazide - Cadmium Therapy “has been conducted in our clinic, on the basis of Medical Centre Ihilov with a small group of oncological patients-volunteers.

The therapy includes simultaneous application of semicarbazide hydrochloride and other medicines in a combination with metallic ionic complexes on the basis of cadmium and gadolinium. The purpose of our research was an estimation of safety and tolerability of the method at application as monotherapy for the stationary and out-patient oncological patients receiving palliative treatment.

The treatment was carried out from permission of Medical Management Centre of “Semicarbazide - Cadmium Therapy” in Germany (the owner: Dr.med. Leo Kacugin, Germany).

After passing training in Germany, we obtained permission from owners to the licensed application of the treatment in Israel on base of our clinic. We also obtained a working know-how of this technologies.

The application of the therapy revealed its good tolerance, safety and efficiency.

Serious side effects were not observed. Hematological parameters including biochemical, remained in limits of norm. On the base of the results we decided to include the medical technology in tools of our clinic.

Now, in the cooperation with Medical Management Centre of “Semicarbazide - Cadmium Therapy”, we develop a model of an ambulatory treatment for oncological patients in territory of Israel. Also we started researches on learning possibilities of a combination of the given therapy with known Revici method.

Successful experience of the application of semacarbazid-cadmium method in our clinic, has allowed us to offer the therapies for oncological patients from other countries.

Our clinical researches confirm a high potential of metallic medicines on the basis of cadmium and preparations of semicarbazide group in oncology.